Oruka Therapeutics (ORKA) Free Cash Flow (2010 - 2026)

Oruka Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$23.7 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 13.26% year-over-year to -$23.7 million; the TTM figure through Mar 2026 stood at -$91.2 million (down 16.06% YoY), while the FY2025 annual figure was -$88.4 million, down 52.38% from the prior year.
• Free Cash Flow was -$23.7 million for Q1 2026 at Oruka Therapeutics, down from -$22.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$168000.0 in Q1 2024 to a low of -$27.8 million in Q3 2024.
• Historically, Free Cash Flow has averaged -$10.9 million across 5 years, with a median of -$4.3 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow jumped 89.47% in 2024, then sank 12329.76% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$1.5 million in 2022, then gained by 29.32% to -$1.1 million in 2023, then sank by 1683.71% to -$18.8 million in 2024, then retreated by 20.37% to -$22.7 million in 2025, then declined by 4.31% to -$23.7 million in 2026.
• The last three Free Cash Flow figures came in at -$23.7 million (Q1 2026), -$22.7 million (Q4 2025), and -$21.7 million (Q3 2025), per Business Quant data.